Ambispective Observational Multicenter Study on the Efficacy of the Third Dose of Vaccine Anti COVID-19 in Patients Suffering From Solid Tumors Undergoing Oncological Treatment Active.

Inclusion criteria

• ✓. Patients aged 18 years or older, regardless of gender;
• ✓. Life expectancy (estimated by the treating doctor) ≥ 6 months;
• ✓. Histological diagnosis confirmed solid neoplasm;
• ✓. Under active treatment
• ✓. Previous two doses of Pfizer anti-SARS-CoV-2 vaccine received (will be considered also patients who have completed the vaccination cycle with other mRNA vaccines - Modern-)
• ✓. All participants subscribed and signed the informed consent form first of enlistment
• ✓. Patients with a positive history of a previous diagnosis are also enrolled laboratory confirmed COVID-19
• ✓. ECOG 0-2